Categories Analysis, Health Care

Key takeaways from Pfizer’s (PFE) Q3 2023 earnings results

Adjusted EPS is expected to range between $1.45-1.65 in FY2023

Shares of Pfizer Inc. (NYSE: PFE) were down on Tuesday, after the company delivered lackluster results for the third quarter of 2023. Total revenues declined due to a drop in COVID-19 products revenue, and the company posted a net loss for the quarter. On the flip side, revenue from non-COVID products witnessed growth. In addition, Pfizer reaffirmed its guidance for the full year of 2023.

Quarterly numbers

Pfizer’s total revenues in the third quarter of 2023 decreased 42% year-over-year to $13.2 billion. The decline was caused by lower revenues from its COVID-19 products, Paxlovid and Comirnaty.

The company reported a net loss of $0.42 per share on a reported basis and $0.17 per share on an adjusted basis in Q3. This compares to reported EPS of $1.51 and adjusted EPS of $1.78 recorded in the prior-year period. The losses were the result of lower sales of COVID-19 products, and non-cash inventory write-offs and other charges.

COVID and non-COVID products

In the third quarter, Pfizer saw a decrease in revenues from its COVID-19 products – Comirnaty and Paxlovid. Comirnaty revenues declined 70% YoY to $1.30 billion, mainly due to lower contracted deliveries within the US and in international markets, as well as lower international demand.

Paxlovid revenues decreased 97% YoY to $202 million in Q3, driven mainly by no US sales in anticipation of commercial transition, and lower contractual deliveries in most international markets.

Meanwhile, the company’s non-COVID products performed well, with revenue growing 10% operationally versus the prior-year quarter. Products like Abrysvo, Vyndaqel and Prevnar also contributed to the revenue growth in the quarter.

For the full year of 2023, Pfizer expects Comirnaty revenues of approx. $11.5 billion, which represents a decline of 70% from 2022. Paxlovid revenues are expected to be around $1 billion, down 95% from last year. The company expects revenue from non-COVID products to grow 6-8% on an operational basis in FY2023.


Pfizer expects revenues to range between $58-61 billion in FY2023, representing a YoY decline of 39-42%. The drop in revenues is due to expected revenue declines for COVID-19 products. Adjusted EPS is expected to range between $1.45-1.65, representing a YoY decrease of 75-78%.

Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.

Most Popular

DG Earnings Preview: What to look for when Dollar General reports Q3 results

Discount store chain Dollar General Corporation (NYSE: DG) will be reporting third-quarter results next week. Operating nearly 20,000 stores across the US, it is one of the largest supermarket chains

Dollar Tree (DLTR): A few points to note about the discount retailer’s Q3 performance

Shares of Dollar Tree, Inc. (NASDAQ: DLTR) were up over 1% on Thursday. The stock has dropped 13% year-to-date. The discount retailer delivered third-quarter 2023 earnings results that did not

KR Earnings: Key quarterly highlights from Kroger’s Q3 2023 financial results

The Kroger Co. (NYSE: KR) reported its third quarter 2023 earnings results today. Total company sales were $34 billion compared to $34.2 billion for the same period last year. Identical sales

Add Comment
Viewing Highlight